Panoramica di mercato

The global single cell bioinformatics software and services market was valued at $205 milioni di euro 2020 and is projected to grow at a CAGR of 10.89% to reach $635 milioni di 2031. The growth of this market can be attributed to the increasing availability of bioinformatics services for computational analysis and the emergence of open-source platforms offering single cell analysis software.

Advancements in bioanalytical technologies have significantly contributed to the study of metabolites, transcripts, and proteins in single cells. This has enabled researchers to better understand cellular heterogeneity and its role in normal and impaired processes. Tuttavia, analyzing single cell data requires specialized bioinformatics tools due to amplification biases and differences between individual cells that may not be captured by traditional bulk-cell data analysis methods.

The presence of major service providers in regions like North America and Europe, such as Illumina, Inc. and QIAGEN, has a positive impact on market growth. These companies offer clinical sequencing bioinformatics services and tailored bioinformatics solutions, respectively, which enhance the quality and convenience of single cell analysis.

The COVID-19 pandemic has also spurred research in single cell analysis, particularly in studying the progression of the disease and its molecular and immune characteristics. Through single cell sequencing and other techniques, researchers have gained insights into immune cell proportions, adaptive immune responses, and gene expression patterns in COVID-19 patients. These studies have highlighted the importance of analyzing organ-level damage and targeting inflammatory pathways for the improved prognosis of severely infected patients.

Demand drivers for the single cell bioinformatics software and services market include the rapid development of single cell technologies, advancements in disease diagnosis and drug discovery, and investments by biopharmaceutical companies. Tuttavia, there are limitations and challenges to overcome, including analytical difficulties in metabolite analysis, the lack of spatial-temporal context in single cell data, and barriers to conducting effective single cell analysis.

Segmentazione del mercato

Il mercato è segmentato in base a vari fattori, including product, applicazione, utente finale, e regione.

Segmentation by Product
Bioinformatics Software
Bioinformatics Services

Segmentazione per applicazione
Oncology
Immunology
Neurology
Non-invasive Prenatal Diagnosis (NIPD)
Microbiology
Other Applications

Segmentazione per utente finale
Research and Academic Institutes
Biopharmaceutical Companies
Altri

Segmentazione per regione
Nord America – NOI., Canada
Europa – U.K., Germania, Francia, Italia, Spagna, e Resto d'Europa
Asia-Pacifico – Giappone, Cina, India, Corea del Sud, Australia, e resto dell'Asia-Pacifico
America Latina – Brasile, Messico, and Rest of Latin America
Rest-of-the-World

The products segment of the global single cell bioinformatics software and services market is projected to be primarily led by the bioinformatics services segment. This is attributed to an increasing number of bioinformatics service providers offering their services to end users. In 2020, the bioinformatics services segment held the largest market share of 94.58% in the global single cell bioinformatics software and services market. Tuttavia, the market share of bioinformatic sequence analysis software is expected to increase and reach 4.12% by 2031. The growth of the bioinformatics services segment is primarily driven by the growing emphasis on adopting bioinformatics services for diagnosing various diseases. Inoltre, the presence of market players like Illumina, Inc. providing services to end users further contributes to market growth.

The oncology segment dominates the global single cell bioinformatics software and services market due to the increasing number of cancer patients. According to the World Health Organization, cancer is a leading cause of death, accounting for nearly 10 million deaths in 2020. In 2020, the oncology segment held the highest market share of 29.81% in the application segment of the global single cell bioinformatics software and services market. This dominance can be attributed to the rising prevalence of cancer and the majority of single cell research being conducted in the field of oncology. Immunology is the second-largest field, following oncology, and it is experiencing consistent growth, mainly due to the impact of the COVID-19 pandemic, which has increased the use of single cell analysis in immunology research.

The research and academic institutes segment dominates the global single cell bioinformatics software and services market due to increasing research and development activities in academic institutions and the focus of researchers on single cell analysis. In 2020, the biopharmaceutical companies segment held a market share of 42.67% among end users in the global single cell bioinformatics software and services market. Mission Bio, a biotechnology company based at the University of California, San Francisco, provides its services to various end users, including pharmaceutical companies, ospedali, and researchers. Inoltre, as technology advances, the costs associated with single cell analysis are expected to decrease, making it more affordable for end users.

North America generated the highest revenue of $103 milioni di euro 2020 in the global single cell bioinformatics software and services market. This can be attributed to advancements in research and development in the field of single cell analysis and the presence of dominant players in the market. In 2020, the North America single cell bioinformatics software and services market held the largest market share globally and is expected to maintain its dominance throughout the forecast period of 2021-2031. Tuttavia, the Asia Pacific (APAC) regione, consisting of several emerging economies, is projected to register the highest compound annual growth rate (CAGR) Di 12.00% during the forecast period of 2021-2031.

Panorama competitivo

The selection of the profiled companies was made following a rigorous process that involved gathering inputs from primary experts and conducting thorough analyses of their company coverage, portafoglio prodotti, e penetrazione del mercato.

Key companies profiled in this report include Fluidigm Corporation, QIAGEN, Mission Bio, Illumina, Inc., Takara Inc., BD., PacBio.

Recenti sviluppi del settore

In December 2019, Nanostring entered into a strategic licensing agreement for diagnostic equipment based on nCounter for single cell analysis. The agreement included acquiring rights to Veracyte for $50 million and Veracyte stock, with the potential for an additional $10 million based on the fulfillment of future events.

In June 2021, Bruker Corporation introduced the Tims TOF SCP system, a cutting-edge technology designed for quantitative single-cell 4D-Proteomics.

In September 2019, IsoPlexis expanded its market reach in the Japanese pharmaceutical and life sciences industry by partnering with BioStream Co. This collaboration enabled the sales expansion of IsoPlexis’ single-cell proteomic research platforms, IsoLight and IsoCode Chip, in Japan.

A gennaio 2021, IsoPlexis launched a groundbreaking solution for spatial biology, offering high-speed imaging capabilities for whole slide analysis at both single-cell and sub-cellular resolution. This innovation set a new standard in the field of spatial biology research.

Risposte alle domande chiave

How is the field of single cell analysis being revolutionized by single cell bioinformatics software and services?

What are the major market drivers, challenges, and opportunities in the global market for single cell bioinformatics software and services?

What are the underlying factors contributing to the emerging trends in the global market for single cell bioinformatics software and services?

How has the COVID-19 pandemic impacted the ecosystem of global single cell bioinformatics software and services?

What are the key strategies being implemented by major players in order to sustain their competitiveness in the market?

What are the regulatory implications related to the use of single cell bioinformatics software and services in developed and developing regions?

What potential entry barriers are expected to be encountered by companies seeking to enter specific regions?

How is each segment of the market projected to grow during the forecast period from 2021 A 2031, and what revenue is anticipated for each segment?

What growth opportunities exist for companies operating in their respective regions?

Which leading players offer significant products and services in the global market for single cell bioinformatics software and services?

Which companies are anticipated to have a highly disruptive impact in the future, and what are the reasons behind this anticipation?